Use of the prostate-specific membrane antigen (PSMA) as a target in prostate cancer imaging is well established and the ligand [68Ga]Ga-PSMA-11 (gallium Ga68 gozetotide), first reported by investigators at the German Cancer Research Center and Heidelberg University (Schäfer et al. 2012; Eder et al. 2013; Sachpekidis et al. 2016) is established for the PET imaging of prostate cancer today (Barrio et al. 2016; Clore and Scott 2024). Here, FOLH1 is linked to prostate carcinoma.